Intellia Therapeutics Head office building

Investors
& Media

Banner Menu

Press Releases

Intellia Therapeutics Announces Proposed Public Offering of Common Stock

Read More

Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema

Read More

Upcoming
Events

More events are coming soon.

Stock Information

Minimum 15 minutes delayed. Source: LSEG